Please login to the form below

Not currently logged in
Email:
Password:

advanced breast cancer

This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’ s Genetech nabs speedy review for Tecentriq in first-line breast cancer. ... The company is seeking approval for first-line use of the drug in combination with Abraxane (chemotherapy) to treat unresectable locally advanced or metastatic

Latest news

  • Soon-Shiong presents first data on cancer memory vaccine at SITC Soon-Shiong presents first data on cancer memory vaccine at SITC

    NK) cells, tumour antigens and drugs achieved tumour responses in heavily pre-treated patients with advanced cases of triple-negative breast cancer, head and neck cancer, and pancreatic cancer. ... Two of three breast cancer patients had a partial

  • Novartis claims a rare win at ESMO for PI3K inhibitor class Novartis claims a rare win at ESMO for PI3K inhibitor class

    Analysts predict drug could hit $1.5bn annual sales. Novartis has bucked a recent disappointing trend among PI3K inhibitors, scoring a win in advanced breast cancer with its alpelisib candidate in ... Around 40% of HR+ advanced breast cancer patients

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    In breast cancer, Novartis will be presenting its SOLAR-1 study of alpha-specific PI3K inhibitor alpelisib (BYL719) in HR+/HER2- advanced breast cancer with PIK3CA mutations, and Clovis Oncology’s ... VEGF/FGF/PDGF inhibitor will give an update on

  • Lilly gets EMA nod for Verzenio in breast cancer Lilly gets EMA nod for Verzenio in breast cancer

    Lilly gets EMA nod for Verzenio in breast cancer. And puts pressure on Pfizer’s market leading Ibrance and Novartis’Kisqali. ... Verzenio (abemaciclib) has been cleared by the EMA to treat women with hormone receptor-positive (HR+), epidermal growth

  • Novartis considers filings for PI3K drug in breast cancer Novartis considers filings for PI3K drug in breast cancer

    Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals. ... Approximately 40% of HR+ advanced breast cancer patients have PIK3CA

More from news
Approximately 1 fully matching, plus 150 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... In October the FDA also approved Talzenna (talazoparib), a new treatment of deleterious or

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being

  • Digital disruption Digital disruption

    Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... This would complement Pfizer's palbococlib, launched in the US in February 2015, to treat HR+/HER2 metastatic

  • Pharma deals during July 2014 Pharma deals during July 2014

    Seragon's focus is in hormone dependent cancers and specifically the development of its Selective Estrogen Receptor Degrader (SERD) platform of oral, small molecule therapeutics for breast and other cancers. ... The lead SERD compound, ARN-810, is

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • FALCON trial of fulvestrant for advanced breast cancer

    FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics